Health-related Quality of Life with Adjuvant Nivolumab After Radical Resection for High-risk Muscle-invasive Urothelial Carcinoma: Results from the Phase 3 CheckMate 274 Trial-Reference-Cited by-同舟云学术

Health-related Quality of Life with Adjuvant Nivolumab After Radical Resection for High-risk Muscle-invasive Urothelial Carcinoma: Results from the Phase 3 CheckMate 274 Trial

Published:2022-10 Issue:5 Volume:5 Page:553-563
ISSN:2588-9311
Container-title:European Urology Oncology
language:en
Short-container-title:European Urology Oncology

Author:

Witjes Johannes Alfred,Galsky Matthew D.,Gschwend Jürgen E.,Broughton Edward,Braverman Julia,Nasroulah Federico,Maira-Arce Mario,Ye Xiaomei,Shi Ling,Guo Shien,Hamilton Melissa,Bajorin Dean F.

Funder

Bristol-Myers Squibb Co

Publisher

Elsevier BV

Subject

Urology,Radiology, Nuclear Medicine and imaging,Oncology,Surgery

Reference40 articles.

1. Incidence, survival and mortality rates of stage-specific bladder cancer in United States: a trend analysis;Abdollah;Cancer Epidemiol,2013

2. European Association of Urology guidelines on muscle-invasive and metastatic bladder cancer: summary of the 2020 guidelines;Witjes;Eur Urol,2021

3. Trends in the utilization of neoadjuvant chemotherapy in muscle-invasive bladder cancer: results from the National Cancer Database;Zaid;Urology,2014

4. Discerning patterns and quality of neoadjuvant chemotherapy use among patients with muscle-invasive bladder cancer;Huo;Eur Urol Oncol,2019

5. No increased risk of short-term complications after radical cystectomy for muscle-invasive bladder cancer among patients treated with preoperative chemotherapy: a nation-wide register-based study;Jerlstrom;World J Urol,2020

Cited by 8 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Enhancing immunotherapy through PD‐L1 upregulation: the promising combination of anti‐PD‐L1 plus mTOR inhibitors;Molecular Oncology;2024-09-11

2. Cost-effectiveness of nivolumab versus surveillance for the adjuvant treatment of patients with urothelial carcinoma who are at high risk of recurrence: a US payer perspective;Journal of Medical Economics;2024-04-04

3. Shame in patients undergoing ureterostomy: A cross‐sectional survey;International Wound Journal;2024-03

4. Perioperative immunotherapy for esophageal squamous cell carcinoma;Frontiers in Immunology;2024-02-19

5. Bladder cancer;Nature Reviews Disease Primers;2023-10-26